About Clinical Genomics sector in Boston, United States
The Clinical Genomics sector in Boston, United States comprises 24 companies, including 16 funded companies having collectively raised $619M in venture capital money and private equity. Out of these, 10 are Series A+ funded.
Clinical Genomics sector in Boston, United States has seen 5 acquisitions and 1 IPO. This represents almost 25.0% of all such companies - which is higher than the 5.0% exit rate of tech companies in general.
This sector includes companies developing molecular diagnostics solutions that involve the collection and/or analysis of patient's genomic data for purposes of disease diagnostics, risk assessment, therapy selection, precision medicine, or disease surveillance.
Companies developing Amplification Based , Hybridization Based , Sequencing Based and Separation Based in vitro assays are included in this sector. 1) Companies developing in vitro diagnostic tests for animal healthcare
2) Companies that provide digital solutions like an app, software, web portals for the management/treatment of diseases.
3) Companies developing tests other than genomics based assays for the treatment of diseases are excluded.
Key Metrics
Total Companies
Top Companies
Total Funding
Funded Companies
Series A+ Companies
Series C+ Companies
IPOs
Acquisitions
Top Clinical Genomics Companies in Boston, United States
There are 24 Clinical Genomics startups in Boston, United States which include Day Zero Diagnostics, WAVE Life Sciences, Precede, 4D Path, Variantyx. Out of these, 16 startups are funded, with 10 having secured Series A+ funding.
Notably, several of these startups have been founded by alumni of Massachusetts Institute of Technology, Harvard University and Booth School of Business.
Here is the list of top Clinical Genomics startups in Boston, United States
Developer of genome sequencing-based diagnostics for infectious diseases. The company offers diagnostic solutions based on machine learning and genomics for infectious diseases. The assay includes Blood2Bac and BacDetect that uses whole-genome sequencing to identify both infecting species and drug resistance in bacterial infections.
Key facts about Day Zero Diagnostics
- Founded Year: 2016
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $49M
- Investors: Triventures, Sands Capital and 10 Others
- Latest Funding Round: Series B, Sep 20, 2023, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 2 of 155 Competitors
RNA medicines to transform human health, treating rare and common disorders. This is a biotechnology company leveraging RNA-targeting modalities, chemistry innovation, and human genetics insights to deliver scientific breakthroughs. They are focused on developing first- or best-in-class therapeutics with life-changing potential. Their research and development pipeline includes lead programs in areas like Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity. They utilize a proprietary PRISM platform to design and manufacture RNA medicines. The company seeks to improve human potential by addressing serious diseases through innovative science and transformative medicines. They are involved in manufacturing, research, and clinical trials, aiming to pioneer advancements in RNA therapeutics.
Key facts about WAVE Life Sciences
- Founded Year: 2012
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $84M
- Investors: Foresite Capital, RA Capital Management and 8 Others
- Latest Funding Round: Series B, Aug 14, 2015, $*****
- Tracxn Score: 60/100 What is this?
- Competitors Rank: 54 of 867 Competitors
3. Precede
Developer of liquid biopsy platform providing disease-defining biology from blood tests. The platform profiles circulating chromatin and the DNA methylome from plasma. It gives resolution into the dynamic activation of individual genes and pathways. The company partners with developers of new medicines and advances diagnostic tests.
Key facts about Precede
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $57M
- Investors: 5AM Ventures, Lilly Asia Ventures and 6 Others
- Latest Funding Round: Series C, Oct 10, 2023, $*****
- Tracxn Score: 58/100 What is this?
- Competitors Rank: 14 of 277 Competitors
4. 4D Path
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
Key facts about 4D Path
- Founded Year: 2016
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $17.1M
- Latest Funding Round: Series B, May 03, 2023, $*****
- Tracxn Score: 55/100 What is this?
- Competitors Rank: 441 of 4,255 Competitors
5. Variantyx
Provider of genomics data analysis platform for healthcare. The company has developed an integrated platform for the analysis, interpretation, and reporting of NGS data for diagnosis. The diagnostic platform uses whole-genome sequencing (WGS) data generated through collaboration with sequencing partners, automated data analysis with clinical report generation, and interpretation to provide a comprehensive molecular diagnostic service for a wide range of disease areas.
Key facts about Variantyx
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $125M
- Investors: Quark Venture, New Era Capital Partners and 10 Others
- Latest Funding Round: Series C, Apr 26, 2024, $*****
- Tracxn Score: 50/100 What is this?
- Competitors Rank: 14 of 150 Competitors
Companies founded year-on-year in the Clinical Genomics sector in Boston
2 Clinical Genomics startups in Boston were founded in 2021 - this is the most number of startups founded in any year in the last 10 years.
- Total Number of Companies
Year | No. of companies |
|---|---|
2026 | - |
2025 | - |
2024 | - |
2023 | - |
2022 | - |
2021 | 2 |
2020 | - |
2019 | - |
2018 | 1 |
2017 | 2 |
Stage-wise distribution of Clinical Genomics sector companies in Boston
Out of the total 24 Clinical Genomics companies in Boston, 16 have secured funding. Among them, 10 have reached Series A or higher, and 10 to Series B or beyond.
Founded - 24
Funded - 16
Series A+ - 10
Series B+ - 10
Series C+ - 8
Company Stage | No. of companies |
|---|---|
Founded | 24 |
Funded | 16 |
Series A+ | 10 |
Series B+ | 10 |
Series C+ | 8 |
Let us walk you through our Sectors and other offerings
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Funding Trends in the Clinical Genomics sector in Boston
Total funding year-on-year in the Clinical Genomics sector in Boston
The Clinical Genomics sector in Boston saw a total funding of more than $495M in the last 10 years. The most amount of funding was in 2015 at more than $108M.
- Total Funding
Year | Total Funding |
|---|---|
2024 | $36M |
2023 | $86.6M |
2022 | $92.5M |
2021 | $26M |
2020 | $10.6M |
2019 | $15.7M |
2018 | $22M |
2017 | $78.3M |
Recent Funding Rounds in Clinical Genomics in Boston
In the year 2024, till April 2024, Clinical Genomics companies in Boston have raised $36M in equity funding across 1 round.
Here are some recent, important funding rounds in Clinical Genomics companies in Boston:
Company | Round Raised | Amount Raised | Funding Date | Investors |
|---|---|---|---|---|
Series C | 7100 | Apr 26, 2024 | ||
Series C | 7258 | Oct 18, 2023 | ||
Series C | 6128 | Oct 10, 2023 | ||
Series B | 7289 | Sep 20, 2023 | - | |
Series B | 2780 | May 03, 2023 | - |
Top Investors in Clinical Genomics in Boston
RA Capital Management is the top investor in Clinical Genomics companies in Boston based on number of companies invested.
Here are some top investors in Clinical Genomics companies in Boston:
Investor | Location | Top Portfolio Companies |
|---|---|---|
Boston (United States) | ||
San Francisco (United States) | ||
Boston (United States) | ||
London (United Kingdom) | - | |
Palo Alto (United States) | - |
M&A activity in Clinical Genomics sector in Boston
In the year 2019, till June 2019, 1 acquisition happened in Clinical Genomics sector in Boston. Last year, in 2018, a total of 2 acquisitions happened in Clinical Genomics sector in Boston.
Here are some recent, important acquisitions in Clinical Genomics sector in Boston:
Company | Acquisition Type | Acquisition Date | Acquirers |
|---|---|---|---|
Business Acquisition | Jun 06, 2019 | ||
Business Acquisition | Oct 16, 2018 | ||
Business Acquisition | Jun 25, 2018 | ||
Business Acquisition | Jul 31, 2017 | ||
Business Acquisition | Jan 12, 2017 |
Acquisition trends in Clinical Genomics sector in Boston
Here are the acquisition trends in Clinical Genomics sector in Boston:
- Total Number of Acquisitions
Year | No. of companies |
|---|---|
2026 | - |
2025 | - |
2024 | - |
2023 | - |
2022 | - |
2021 | - |
2020 | - |
2019 | 1 |
2018 | 2 |
2017 | 2 |
IPOs in Clinical Genomics in Boston
In the year 2015, till November 2015, 1 IPO happened in Clinical Genomics sector in Boston.
Here are some recent, important IPOs in Clinical Genomics sector in Boston:
Company | IPO Date | Exchange Symbol |
|---|---|---|
Nov 11, 2015 | National Association of Securities Dealers Automated Quotations (NASDAQ) |
Colleges which produce the most Clinical Genomics companies in Boston
Companies founded by alumni from top colleges in the Clinical Genomics in Boston
Most number of Clinical Genomics startups in Boston have been founded by alumni from Massachusetts Institute of Technology, Harvard University and Booth School of Business.
College | No. of companies |
|---|---|
Massachusetts Institute of Technology | 3 |
Harvard University | 2 |
Booth School of Business | 1 |
Cornell University | 1 |
Harvard Business School | 1 |
Tel Aviv University | 1 |
University of Cambridge | 1 |
University of Chicago | 1 |
University of Oxford | 1 |
Total funding in Clinical Genomics companies founded by alumni from top colleges in Boston
In the last 10 years, Tel Aviv University graduates' Clinical Genomics companies in Boston have raised the most funding among top colleges. Massachusetts Institute of Technology alumni are second, and Harvard University alumni are third.
College | Total Funding |
|---|---|
Tel Aviv University | $132M |
Massachusetts Institute of Technology | $81.8M |
Harvard University | $64.7M |
Harvard Business School | $63.6M |
University of Oxford | $57M |
University of Cambridge | $17.1M |
Booth School of Business | - |
Cornell University | - |
University of Chicago | - |
Top News in Clinical Genomics in Boston
•
Wave Life Sciences Announces Positive Update from WVE-006 Trial in AAT DeficiencyGlobeNewswire•Sep 03, 2025•GSK, WAVE Life Sciences
•
•
•
•
•
•
Altoida Appoints Marc Jones as Chief Executive OfficerBusiness Wire•Jun 05, 2023•Altoida, Good Start Genetics
•
•
•
